A randomised controlled trial comparing the effects of micronized progesterone to medroxyprogesterone acetate on cardiovascular health, lipid metabolism and the coagulation cascade in women with premature ovarian insufficiency: study protocol and review of the literature.
Premature ovarian insufficiency (POI) can have significant health implications for the affected patient population, but remains a largely under researched area. There is lack of evidence from randomised controlled trials to guide clinical practice, regarding the optimal hormone replacement therapy regimens, dose and route of administration. Furthermore, little research has addressed the effect of the various progestogens used on health parameters in women with POI. Here we describe an ongoing randomised clinical trial looking at the effects of micronized progesterone and medroxyprogesterone acetate, both used in combination with transdermal oestradiol on the cardiovascular system, lipid profile and coagulation cascade in women with POI as a step towards better understanding of the implications of hormone treatment in this cohort of women.
Assisted Conception Unit, King's College Hospital, London, UK.
Monica
M
Mittal
Michael
M
Savvas
Roopen
R
Arya
Carmel
C
McEniery
Nitish
N
Narvekar
Linda
L
Cardozo
Nick
N
Panay
Haitham
H
Hamoda
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects* / Q000502:physiology; D002318:Cardiovascular Diseases / Q000453:epidemiology; D002319:Cardiovascular System / Q000187:drug effects* / Q000503:physiopathology; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects* / Q000502:physiology; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology* / Q000627:therapeutic use; D016649:Primary Ovarian Insufficiency / Q000188:drug therapy / Q000503:physiopathology*; D011374:Progesterone / Q000494:pharmacology* / Q000627:therapeutic use; D012307:Risk Factors; D016896:Treatment Outcome; D055815:Young Adult
D011374:Progesterone; D004958:Estradiol; D017258:Medroxyprogesterone Acetate
HRT; Menopause; estrogen